Q1 2025 Earnings Forecast for Apellis Pharmaceuticals, Inc. Issued By Zacks Research (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for Apellis Pharmaceuticals in a research report issued on Tuesday, April 23rd. Zacks Research analyst R. Department now anticipates that the company will post earnings of ($0.01) per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at $0.39 EPS and FY2025 earnings at $1.05 EPS.

A number of other equities analysts have also weighed in on APLS. Raymond James upped their target price on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research report on Thursday, January 11th. HC Wainwright reissued a “buy” rating and issued a $92.00 price target on shares of Apellis Pharmaceuticals in a research report on Friday. JPMorgan Chase & Co. increased their price target on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Mizuho restated a “neutral” rating and issued a $60.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Robert W. Baird restated an “outperform” rating and issued a $81.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $77.93.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $49.86 on Thursday. Apellis Pharmaceuticals has a 52-week low of $19.83 and a 52-week high of $94.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. The business’s 50 day moving average price is $58.21 and its two-hundred day moving average price is $57.30. The firm has a market cap of $6.01 billion, a PE ratio of -11.31 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business had revenue of $146.38 million for the quarter, compared to analysts’ expectations of $143.34 million. During the same period in the prior year, the business posted ($1.50) earnings per share. The firm’s revenue was up 545.9% on a year-over-year basis.

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of APLS. Jennison Associates LLC raised its holdings in shares of Apellis Pharmaceuticals by 79.8% in the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock valued at $134,746,000 after acquiring an additional 1,571,606 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after acquiring an additional 1,121,497 shares in the last quarter. Norges Bank purchased a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at about $56,640,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Apellis Pharmaceuticals by 38.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after acquiring an additional 677,098 shares in the last quarter. Finally, Polar Capital Holdings Plc raised its holdings in shares of Apellis Pharmaceuticals by 126.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after buying an additional 588,875 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Apellis Pharmaceuticals news, insider Mark Jeffrey Delong sold 9,913 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $56.90, for a total value of $564,049.70. Following the completion of the transaction, the insider now owns 54,693 shares in the company, valued at approximately $3,112,031.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Insiders sold a total of 381,011 shares of company stock worth $23,463,657 in the last quarter. 7.50% of the stock is owned by company insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).